Figure 2.

Cancer drug library screening reveal the acquired vulnerability of CDK4/6 inhibitor-resistant clones to ribosome biogenesis stress. (A) Acquired vulnerability concept (top). Drugs were considered to be acquired vulnerability-positive when the 5-day area under the cell proliferation curve (AUC) of a resistant clone was lower than 50% of the AUC of the parental cell (left). A small cancer drug library (right). (B) Heat map showing the relative sensitivity of each KKU-055-resistant clone compared to KKU-055wt (less sensitive: blue, more sensitive: red). (C) Oxaliplatin dose-response curves for KKU-055wt, KKU-213B, and their pooled resistant cells. (D) Oxaliplatin dose-response curves for KKU-055wt and resistant clones. (E) Oxaliplatin dose-response curves for KKU-213Bwt and resistant clones.